c-Jun and Fra-2 pair up to Myc-anistically drive HCC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer death with limited treatment options.
• HCC development is linked to Hepatitis Virus infection and metabolic syndrome.
• Genetically engineered mouse models (GEMMs) are vital for studying HCC pathogenesis.

Purpose of the Study:

• To investigate the role of Activator Protein-1 (AP-1) dimers in HCC development using GEMMs.
• To identify molecular determinants of HCC formation and potential therapeutic targets.

Main Methods:

• Utilized GEMMs with switchable, hepatocyte-restricted expression of a c-Jun~Fra-2 AP-1 mimic.
• Analyzed early-stage tumor development, including cell cycle, inflammation, and dyslipidemia.
• Assessed molecular signatures of HCC and therapeutic targeting of c-Myc.

Main Results:

• AP-1 GEMMs spontaneously developed largely reversible liver tumors.
• Early stages showed dysregulated cell cycle, inflammation, and dyslipidemia.
• Increased c-Myc expression was essential for tumor formation and responsive to BET inhibitor JQ1.

Conclusions:

• AP-1 dimers play a critical role in HCC pathogenesis.
• c-Myc is a key molecular driver and a viable therapeutic target in HCC.
• AP-1 GEMMs provide a valuable platform for preclinical liver disease research.